Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, and Breast Cancer Treatment Studies.
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast Cancer.
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling.
Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Mapping breast cancer therapy with circulating tumor cells: The expert perspective
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer
LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them.
Mapping breast cancer therapy with circulating tumor cells: The expert perspective.
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
Liquid biopsy in breast cancer: Redefining precision medicine
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer.
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.
FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancer
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.
Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity.
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Supplementary Figure S5 from Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity
Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer